Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Purine sensors as novel point-of-care devices for seizures and epilepsy

Project description

Epilepsy: a point-of-care diagnostic tool

Even though epilepsy affects millions of people around the world, its diagnosis still depends largely on clinical observation. Emerging evidence shows that cell-to-cell communication through adenosine triphosphate (ATP) and nucleotides – called purinergic signalling – plays a role in triggering seizures and could serve as a biomarker for epilepsy. With the support of the Marie Skłodowska-Curie Actions programme, the ATPsensor project aims to develop a simple, non-invasive point-of-care sensor capable of detecting specific purine molecules in blood samples. Researchers will optimise and test this innovative device in preclinical models of epilepsy and patient samples. The goal is to assess purine expression changes and evaluate their potential in epilepsy diagnosis.

Objective

Epilepsy is the most common chronic brain disease, affecting ~70 million people worldwide. Accurately diagnosing epilepsy remains a major clinical challenge due to the lack of non-invasive molecular diagnostic tools. Purinergic signalling via extracellularly released adenosine triphosphate (ATP) and its downstream purine derivatives is increasingly recognised to contribute to increased hyperexcitability states in the brain, and thus seizures. Hence, these can be potentially identified as novel promising therapeutic targets for the treatment of epilepsy but also as a source of disease-specific biomarkers. However, the diagnostic potential of purinergic signalling for epilepsy remains unclear, and current methods of detection are either unsuitable for point-of-care application or lack disease specificity. Employing a multidisciplinary approach including sensor development, testing in preclinical models of epilepsy, and testing in patients, we will develop a new, user-friendly point-of-care sensor which allows the measurement of specific purines and evaluate the diagnostic potential of blood purine expression changes. Combining my research experience in the development of biosensors with the expertise of my primary (Dr Tobias Engel, RCSI) and secondment (Prof Nicholas Dale, University of Warwick; Prof Norman Delanty, Beaumont Hospital; Prof Felix Rosenow, Frankfurt University) supervisors on purinergic signalling and the development diagnostic devices, ATPsensor will increase our understanding of purinergic signalling and provide new tools to support the diagnosis of epilepsy. The skills acquired during the research project, the excellent training record of the supervisors and host institutions, and the outstanding resources for learning and development available at RCSI and collaborator institutions will give me the tools necessary to become a highly employable neuroscientist.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2023-PF-01

See all projects funded under this call

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND
Net EU contribution
€ 199 694,40
Address
ST STEPHEN GREER 123
D02 YN77 DUBLIN 2
Ireland
Region
Ireland Eastern and Midland Dublin
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (4)